Free Trial

Swedish Orphan Biovitrum AB (publ) Q4 2023 Earnings Report

Swedish Orphan Biovitrum AB (publ) logo
$28.62 0.00 (0.00%)
(As of 12/20/2024 ET)

Swedish Orphan Biovitrum AB (publ) EPS Results

Actual EPS
$0.30
Consensus EPS
$0.56
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Swedish Orphan Biovitrum AB (publ) Revenue Results

Actual Revenue
$643.39 million
Expected Revenue
$668.74 million
Beat/Miss
Missed by -$25.35 million
YoY Revenue Growth
N/A

Swedish Orphan Biovitrum AB (publ) Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Swedish Orphan Biovitrum AB (publ) Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Swedish Orphan Biovitrum AB (publ) Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum AB (publ)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum AB (publ) and other key companies, straight to your email.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

View Swedish Orphan Biovitrum AB (publ) Profile

More Earnings Resources from MarketBeat

Upcoming Earnings